市場調査レポート
商品コード
1589210

クリティカルケア治療薬市場:薬剤クラス別、用途別-2025-2030年の世界予測

Critical Care Therapeutics Market by Drug Class (Albumin, Antithrombin Concentrates, Factor XIII Concentrates), Application (Acute Coronary Syndrome, Atrial Fibrillation, Coronary Angioplasty) - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 199 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.91円
クリティカルケア治療薬市場:薬剤クラス別、用途別-2025-2030年の世界予測
出版日: 2024年10月31日
発行: 360iResearch
ページ情報: 英文 199 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

クリティカルケア治療薬市場は、2023年に47億7,000万米ドルと評価され、2024年には50億3,000万米ドルに達すると予測され、CAGR 5.39%で成長し、2030年には69億米ドルに達すると予測されています。

クリティカルケア治療薬には、重症感染症、臓器不全、術後の重篤な状態など、集中的なモニタリングとサポートを必要とする生命を脅かす状態の治療に焦点を当てた、幅広い医療ソリューションが含まれます。このような治療薬の必要性は、慢性疾患の蔓延、人口の高齢化、専門的なケアを必要とする危機的な健康状態の発生率の増加から生じています。用途は、病院や専用の集中治療室(ICU)などさまざまなヘルスケア環境にまたがり、最終用途は成人および小児医療に及ぶ。市場開拓の主な要因としては、バイオテクノロジーや医薬品の進歩が挙げられ、これにより標的治療や個別化医療ソリューションが開発されるようになった。さらに、AIを活用した診断や遠隔集中治療室などのデジタルヘルス技術は、市場拡大の有望な機会となっています。医療従事者やヘルスケア施設は、これらの技術を活用して患者の転帰や業務効率を高めることができます。しかし、治療コストの高さ、規制要件の厳しさ、先進的治療薬に伴う副作用の可能性などから、市場は限界に直面しています。さらに、COVID-19パンデミックはヘルスケア・インフラの脆弱性を露呈させ、クリティカル・ケア・サービスの適応性と資源配分に困難をもたらしました。成長機会を生かすために、利害関係者はより費用対効果の高い治療が期待できるバイオシミラーとモノクローナル抗体の技術革新に注目すべきです。さらに、ウェアラブル健康モニタリング技術への投資とビッグデータ分析の統合は、患者管理とケア経路の最適化に関する洞察を提供することができます。市場は本質的にダイナミックで競合情勢に満ちているため、継続的なイノベーションと進化するヘルスケア情勢への適応が必要となります。企業は共同研究イニシアチブを優先し、セクターを超えたパートナーシップを強化して成長を促進すべきです。最新の治療薬やテクノロジーに関するヘルスケア専門家の教育やトレーニングを重視することで、クリティカルケア治療薬の領域における市場浸透と持続可能性の成功をさらに促進することができます。

主な市場の統計
基準年[2023] 47億7,000万米ドル
予測年[2024] 50億3,000万米ドル
予測年[2030] 69億米ドル
CAGR(%) 5.39%

市場力学:急速に進化するクリティカルケア治療薬市場の主要市場インサイトを公開

クリティカルケア治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 世界の老人人口の増加と慢性疾患の有病率の増加
    • デジタル化の動向と、座りっぱなしのライフスタイルによる病気
    • 近代的治療施設のためのヘルスケア分野への大規模投資
  • 市場抑制要因
    • 治療薬の高コスト
  • 市場機会
    • クリティカルケア診断の導入に向けた政府の活動と支援
    • 診断と検査室間の遠隔通信の増加
  • 市場の課題
    • 熟練した専門家の不足

ポーターの5つの力:クリティカルケア治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:クリティカルケア治療薬市場における外部からの影響の把握

外部マクロ環境要因は、クリティカルケア治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析クリティカルケア治療薬市場における競合情勢の把握

クリティカルケア治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスクリティカルケア治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、クリティカルケア治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨クリティカルケア治療薬市場における成功への道筋を描く

クリティカルケア治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています:

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で高齢者人口が増加し、慢性疾患の罹患率も増加
      • デジタル化の動向と座りっぱなしの生活習慣による病気
      • 近代的な医療施設のためのヘルスケア分野への大規模な投資
    • 抑制要因
      • 治療費の高騰
    • 機会
      • 集中治療診断の実施に向けた政府の活動と支援
      • 診断と検査室間の遠隔通信の増加
    • 課題
      • 熟練した専門家の不足
  • 市場セグメンテーション分析
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境

第6章 クリティカルケア治療薬市場薬剤クラス別

  • アルブミン
  • 抗トロンビン濃縮物
  • 因子XIII濃縮物
  • フィブリノゲン濃縮物
  • プロトロンビン複合体濃縮物

第7章 クリティカルケア治療薬市場:用途別

  • 急性冠症候群
  • 心房細動
  • 冠動脈形成術
  • 深部静脈血栓症
  • 血液透析
  • 肺塞栓症
  • 手術

第8章 南北アメリカのクリティカルケア治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域のクリティカルケア治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカのクリティカルケア治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
  • 戦略分析と提言

企業一覧

  • Abeona Therapeutics Inc.
  • ADMA Biologics, Inc.
  • Albumedix Ltd. by Sartorius AG
  • Asklepios BioPharmaceutical, Inc.
  • Aspen Group
  • Bio Products Laboratory Ltd.
  • BioDelivery Sciences International, Inc.
  • Biotest AG
  • CSL Limited
  • Grifols SA
  • Kedrion Spa
  • Novartis AG
  • Octapharma AG
  • Shanghai RAAS
  • Takeda Pharmaceutical Co. Ltd.
図表

LIST OF FIGURES

  • FIGURE 1. CRITICAL CARE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. CRITICAL CARE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CRITICAL CARE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CRITICAL CARE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CRITICAL CARE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CRITICAL CARE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTITHROMBIN CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY FACTOR XIII CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY FIBRINOGEN CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CORONARY ANGIOPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SURGERIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. EGYPT CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. EGYPT CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. FINLAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. FINLAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. FRANCE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. FRANCE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. GERMANY CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. GERMANY CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ISRAEL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. ISRAEL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ITALY CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. ITALY CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. NETHERLANDS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. NETHERLANDS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. NIGERIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. NIGERIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. NORWAY CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. NORWAY CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. POLAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. POLAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. QATAR CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. QATAR CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. RUSSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. RUSSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SAUDI ARABIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. SAUDI ARABIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SPAIN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. SPAIN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SWEDEN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. SWEDEN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SWITZERLAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. SWITZERLAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. TURKEY CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. TURKEY CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED ARAB EMIRATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED ARAB EMIRATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED KINGDOM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED KINGDOM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. CRITICAL CARE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 108. CRITICAL CARE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-4311CE1A33EE

The Critical Care Therapeutics Market was valued at USD 4.77 billion in 2023, expected to reach USD 5.03 billion in 2024, and is projected to grow at a CAGR of 5.39%, to USD 6.90 billion by 2030.

Critical care therapeutics encompasses a broad array of medical solutions focused on treating life-threatening conditions requiring intensive monitoring and support, such as severe infections, organ failures, and critical post-operative states. The necessity for such therapeutics arises from the growing prevalence of chronic diseases, an aging population, and the increasing incidence of critical health situations necessitating specialized care. Applications span across various healthcare settings, including hospitals and dedicated intensive care units (ICUs), with end-use encompassing both adult and pediatric care. Key growth influencers in the market involve advancements in biotechnology and pharmaceuticals, which have led to the development of targeted therapies and personalized medicine solutions. Additionally, digital health technologies, such as AI-driven diagnostics and tele-intensive care units, present promising opportunities for market expansion. Medical professionals and healthcare facilities could leverage these technologies to enhance patient outcomes and operational efficiencies. However, the market faces limitations due to high treatment costs, stringent regulatory requirements, and potential side effects associated with advanced therapeutics. Furthermore, the COVID-19 pandemic exposed vulnerabilities in healthcare infrastructure, challenging the adaptability and resource allocation of critical care services. To capitalize on growth opportunities, stakeholders should focus on innovation in biosimilars and monoclonal antibodies, which promise more cost-effective treatments. Additionally, investment in wearable health monitoring technologies and integration of big data analytics can offer insights into patient management and optimized care pathways. The market is inherently dynamic and competitive, necessitating continuous innovation and adaptation to the evolving healthcare landscape. Companies should prioritize collaborative research initiatives and enhance cross-sector partnerships to drive growth. Emphasizing education and training for healthcare professionals on the latest therapeutics and technologies can further facilitate successful market penetration and sustainability in the domain of critical care therapeutics.

KEY MARKET STATISTICS
Base Year [2023] USD 4.77 billion
Estimated Year [2024] USD 5.03 billion
Forecast Year [2030] USD 6.90 billion
CAGR (%) 5.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Critical Care Therapeutics Market

The Critical Care Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising geriatric population worldwide and increase in prevalence of chronic diseases
    • Adoption of digitization trends and illness due to sedentary lifestyle
    • Large investments in the healthcare sector for modern medical treatments facilities
  • Market Restraints
    • High cost of therapeutics
  • Market Opportunities
    • Government activities and support for implementing critical care diagnostics
    • Rising remote communications between diagnostics and laboratories
  • Market Challenges
    • Lack of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the Critical Care Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Critical Care Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Critical Care Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Critical Care Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Critical Care Therapeutics Market

A detailed market share analysis in the Critical Care Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Critical Care Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Critical Care Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Critical Care Therapeutics Market

A strategic analysis of the Critical Care Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Critical Care Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., ADMA Biologics, Inc., Albumedix Ltd. by Sartorius AG, Asklepios BioPharmaceutical, Inc., Aspen Group, Bio Products Laboratory Ltd., BioDelivery Sciences International, Inc., Biotest AG, CSL Limited, Grifols SA, Kedrion Spa, Novartis AG, Octapharma AG, Shanghai RAAS, and Takeda Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Critical Care Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Albumin, Antithrombin Concentrates, Factor XIII Concentrates, Fibrinogen Concentrates, and Prothrombin Complex Concentrates.
  • Based on Application, market is studied across Acute Coronary Syndrome, Atrial Fibrillation, Coronary Angioplasty, Deep Vein Thrombosis, Hemodialysis, Pulmonary Embolism, and Surgeries.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population worldwide and increase in prevalence of chronic diseases
      • 5.1.1.2. Adoption of digitization trends and illness due to sedentary lifestyle
      • 5.1.1.3. Large investments in the healthcare sector for modern medical treatments facilities
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Government activities and support for implementing critical care diagnostics
      • 5.1.3.2. Rising remote communications between diagnostics and laboratories
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of skilled professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Critical Care Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Albumin
  • 6.3. Antithrombin Concentrates
  • 6.4. Factor XIII Concentrates
  • 6.5. Fibrinogen Concentrates
  • 6.6. Prothrombin Complex Concentrates

7. Critical Care Therapeutics Market, by Application

  • 7.1. Introduction
  • 7.2. Acute Coronary Syndrome
  • 7.3. Atrial Fibrillation
  • 7.4. Coronary Angioplasty
  • 7.5. Deep Vein Thrombosis
  • 7.6. Hemodialysis
  • 7.7. Pulmonary Embolism
  • 7.8. Surgeries

8. Americas Critical Care Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Critical Care Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Critical Care Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. ADMA Biologics, Inc.
  • 3. Albumedix Ltd. by Sartorius AG
  • 4. Asklepios BioPharmaceutical, Inc.
  • 5. Aspen Group
  • 6. Bio Products Laboratory Ltd.
  • 7. BioDelivery Sciences International, Inc.
  • 8. Biotest AG
  • 9. CSL Limited
  • 10. Grifols SA
  • 11. Kedrion Spa
  • 12. Novartis AG
  • 13. Octapharma AG
  • 14. Shanghai RAAS
  • 15. Takeda Pharmaceutical Co. Ltd.